Pharmacodynamic Monitoring of Canine T-Cell Cytokine Responses to Oral Cyclosporine

Journal of Veterinary Internal Medicine

Volumn 25, Issue 6, 2011, Pages 1391-1397

  Archer, T M ^a   Fellman, C L ^a   Stokes, J V ^a   Pinchuk, L M ^a   Lunsford, K V ^a   Pruett, S B ^a   Langston, V C ^a   Mackin, A J ^a  

^a MISSISSIPPI STATE UNIVERSITY   (United States)

Author keywords

Flow cytometry; Interferon gamma; Interleukin 2; Interleukin 4

Indexed keywords

CYCLOSPORIN; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2;

ANIMAL; ARTICLE; CLINICAL TRIAL; DOG; DOSE RESPONSE; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; ORAL DRUG ADMINISTRATION; T LYMPHOCYTE;

ADMINISTRATION, ORAL; ANIMALS; CYCLOSPORINE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; INTERLEUKIN-2; T-LYMPHOCYTES;

ANIMALIA; CANIS FAMILIARIS;

EID: 81355138258     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2011.00797.x     Document Type: Article

References (48)

1. Kapturczak MH, Meier-Kriesche HU, Kaplan B. Pharmacology of calcineurin antagonists. Transplant Proc 2004;36:25S-32S.
2. Murphy K, Travers P, Walport M. Janeway's Immunobiology, 7th ed. New York: Garland Science; 2008.
3. Moore C. Immunomodulating agents. Vet Clin North Am Small Anim Pract 2004;34:725-737.
4. Whitley NT, Day MJ. Immunomodulatory drugs and their application to the management of canine immune-mediated disease. J Small Anim Pract 2011;52:70-85.
5. Rovira P, Mascarell L, Truffa-Bachi P. The impact of immunosuppressive drugs on the analysis of T cell activation. Curr Med Chem 2000;7:673-692.
6. Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: Regulation and function. Ann Rev Immunol 1997;15:707-747.
7. Ho S, Clipstone N, Timmermann L, et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 1996;80:S40-S45.
8. Lan RY, Selmi C, Gershwin ME. The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2). J Autoimmun 2008;31:7-12.
9. Nashan B. The IL2 pathway in clinical immunosuppression. Transplant Proc 2001;33:3072-3074.
10. Steffan J, Strehlau G, Maurer M, et al. Cyclosporin A pharmacokinetics and efficacy in the treatment of atopic dermatitis in dogs. J Vet Pharmacol Ther 2004;27:231-238.
11. Doust R, Griffiths LG, Sullivan M. Evaluation of once daily treatment with cyclosporine for anal furunculosis in dogs. Vet Rec 2003;152:225-229.
12. Pedersen NC. A review of immunologic diseases of the dog. Vet Immunol Immunopathol 1999;69:251-342.
13. Allenspach K, Rufenacht S, Sauter S, et al. Pharmacokinetics and clinical efficacy of cyclosporine treatment of dogs with steroid-refractory inflammatory bowel disease. J Vet Intern Med 2006;20:239-244.
14. House AK, Guitian J, Gregory SP, et al. Evaluation of the effect of two dose rates of cyclosporine on the severity of perianal fistulae lesions and associated clinical signs in dogs. Vet Surg 2006;35:543-549.
15. Clements DN, Gear RN, Tattersall J, et al. Type I immune-mediated polyarthritis in dogs: 39 cases (1997-2002). J Am Vet Med Assoc 2004;224:1323-1327.
16. Grundy SA, Barton C. Influence of drug treatment on survival of dogs with immune-mediated hemolytic anemia: 88 cases (1989-1999). J Am Vet Med Assoc 2001;218:543-546.
17. Jung DI, Kang BT, Park C, et al. A comparison of combination therapy (cyclosporine plus prednisolone) with sole prednisolone therapy in 7 dogs with necrotizing meningoencephalitis. J Vet Med Sci 2007;69:1303-1306.
18. Robson D. Review of the pharmacokinetics, interactions and adverse reactions of cyclosporine in people, dogs and cats. Vet Rec 2003;152:739-748.
19. Griffiths LG, Sullivan M, Borland WW. Cyclosporin as the sole treatment for anal furunculosis: Preliminary results. J Small Anim Pract 1999;40:569-572.
20. Plumb DC. Plumb's Veterinary Drug Handbook, 6th ed. Ames, IA: PharmaVet Inc.; 2008:5.
21. Daigle JC. More economical use of cyclosporine through combination drug therapy. J Am Anim Hosp Assoc 2002;38:205-208.
22. Mathews KA, Sukhiani HR. Randomized controlled trial of cyclosporine for treatment of perianal fistulas in dogs. J Am Vet Med Assoc 1997;211:1249-1253.
23. Mathews KA, Holmberg DL. Kidney transplantation in dogs with naturally occurring end-stage renal disease. J Am Anim Hosp Assoc 2000;36:475.
24. Patterson AP, Campbell KL. Managing anal furunculosis in dogs. Compendium 2005:339-355.
25. Olivry T, Mueller RS. Evidence-based veterinary dermatology: A systematic review of the pharmacotherapy of canine atopic dermatitis. Vet Dermatol 2003;14:121-146.
26. Olivry T, Steffan J, Fisch RD, et al. Randomized controlled trial of the efficacy of cyclosporine in the treatment of atopic dermatitis in dogs. J Am Vet Med Assoc 2002;221:370-377.
27. Bohler T, Nolting J, Kamar N, et al. Validation of immunological biomarkers for the pharmacodynamic monitoring of immunosuppressive drugs in humans. Ther Drug Monit 2007;29:77-86.
28. Barten MJ, Tarnok A, Garbade J, et al. Pharmacodynamics of T-cell function for monitoring immunosuppression. Cell Prolif 2007;40:50-63.
29. Barten MJ, Gummert JF. Biomarkers in transplantation medicine: prediction of pharmacodynamic drug effects. Transfus Med Hemother 2007;34:182-187.
30. Batiuk TD, Kung L, Halloran PF. Evidence that calcineurin is rate-limiting for primary human lymphocyte activation. J Clin Invest 1997;100:1894-1901.
31. Stein CM, Murray JJ, Wood AJ. Inhibition of stimulated interleukin-2 production in whole blood: A practical measure of cyclosporine effect. Clin Chem 1999;45:1477-1484.
32. Fukudo M, Yano I, Masuda S, et al. Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients. Clin Pharmacol Ther 2005;78:168-181.
33. Nam HS, McAnulty JF, Kwak HH, et al. Gingival overgrowth in dogs associated with clinically relevant cyclosporine blood levels: Observations in a canine renal transplantation model. Vet Surg 2008;37:247-253.
34. Strasser A, Kalmar E, Niedermuller H. A simple method for the simultaneous separation of peripheral blood mononuclear and polymorphonuclear cells in the dog. Vet Immunol Immunopathol 1998;62:29-35.
35. Fellman CL, Stokes JV, Archer TM, et al. Cyclosporine A affects the in vitro expression of T cell activation-related molecules and cytokines in dogs. Vet Immunol Immunopathol 2011;140:175-180.
36. Pedersen LG, Castelruiz Y, Jacobsen S, et al. Identification of monoclonal antibodies that cross-react with cytokines from different animal species. Vet Immunol Immunopathol 2002;88:111-122.
37. Taylor JK. Principles of measurement. In: CRC Press, eds. Quality Assurance of Chemical Measurements. Chelsea: Lewis Publishers, Inc; 1987:79-83.
38. Dambrin C, Klupp J, Morris RE. Pharmacodynamics of immunosuppressive drugs. Curr Opin Immunol 2000;12:557-562.
39. Barten MJ, Rahmel A, Boldt A, et al. Pharmacodynamic monitoring of the immunosuppressive therapy in patients after heart transplantation: Whole blood flow cytometric analysis of lymphocyte function. Comput Biol Med 2007;37:1367-1373.
40. Barten MJ, Rahmel A, Bocsi J, et al. Cytokine analysis to predict immunosuppression. Cytometry A 2006;69:155-157.
41. Gilger BC, Andrews J, Wilkie DA, et al. Cellular immunity in dogs with keratoconjunctivitis sicca before and after treatment with topical 2% cyclosporine. Vet Immunol Immunopathol 1995;49:199-208.
42. Tivers MS, Catchpole B, Gregory SP, et al. Interleukin-2 and interferon-gamma mRNA expression in canine anal furunculosis lesions and the effect of ciclosporin therapy. Vet Immunol Immunopathol 2008;125:31-36.
43. Kobayashi T, Momoi Y, Iwasaki T. Cyclosporine A inhibits the mRNA expressions of IL-2, IL-4 and IFN-gamma, but not TNF-alpha, in canine mononuclear cells. J Vet Med Sci 2007;69:887-892.
44. Jergens AE, Sonea IM, O'Connor AM, et al. Intestinal cytokine mRNA expression in canine inflammatory bowel disease: A meta-analysis with critical appraisal. Comp Med 2009;59:153-162.
45. Nuttall TJ, Knight PA, McAleese SM, et al. Expression of Th1, Th2 and immunosuppressive cytokine gene transcripts in canine atopic dermatitis. Clin Exp Allergy 2002;32:789-795.
46. House A, Gregory SP, Catchpole B. Expression of cytokine mRNA in canine anal furunculosis lesions. Vet Rec 2003;153:354-358.
47. Takaori K, Nio Y, Inoue K, et al. A comparative study on immunosuppressive effects of cyclosporin A and FK 506 on peripheral blood lymphocytes in dogs. Biotherapy 1992;4:129-137.
48. Brunet M, Crespo M, Millan O, et al. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic. Transplant Proc 2007;39:2160-2162.